Subscribe
handshake-1
miodrag ignjatovic / iStockphoto.com
3 January 2018Americas

AstraZeneca sells US rights to four drugs for $46.5m

AstraZeneca has sold the US rights and New Drug Applications to four drugs to ANI Pharmaceuticals, a speciality pharmaceutical company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
AstraZeneca sells Seroquel rights for $538m
10 May 2018   AstraZeneca has agreed to sell its rights to Seroquel (quetiapine fumarate) and Seroquel XR to China-based pharmaceutical company Luye Pharma Group for $538 million.
Big Pharma
UK government announces life sciences deal; GSK and AstraZeneca invest
11 December 2017   The UK government has announced a deal between the life sciences sector and the government, aimed at ensuring that the “next wave of breakthrough treatments” and innovative medical research and technologies are created in the country.
Asia
AstraZeneca forms Chinese company to boost innovation
28 November 2017   AstraZeneca and the Chinese Future Industry Investment Fund have partnered to establish a company focused on discovering, developing and commercialising new medicines.


Editor's picks

Bankruptcy judge approves $305m sale of genetics testing company
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025

Editor's picks

Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025

More on this story

Asia-Pacific
AstraZeneca sells Seroquel rights for $538m
10 May 2018   AstraZeneca has agreed to sell its rights to Seroquel (quetiapine fumarate) and Seroquel XR to China-based pharmaceutical company Luye Pharma Group for $538 million.
Big Pharma
UK government announces life sciences deal; GSK and AstraZeneca invest
11 December 2017   The UK government has announced a deal between the life sciences sector and the government, aimed at ensuring that the “next wave of breakthrough treatments” and innovative medical research and technologies are created in the country.
Asia
AstraZeneca forms Chinese company to boost innovation
28 November 2017   AstraZeneca and the Chinese Future Industry Investment Fund have partnered to establish a company focused on discovering, developing and commercialising new medicines.

More on this story

Asia-Pacific
AstraZeneca sells Seroquel rights for $538m
10 May 2018   AstraZeneca has agreed to sell its rights to Seroquel (quetiapine fumarate) and Seroquel XR to China-based pharmaceutical company Luye Pharma Group for $538 million.
Big Pharma
UK government announces life sciences deal; GSK and AstraZeneca invest
11 December 2017   The UK government has announced a deal between the life sciences sector and the government, aimed at ensuring that the “next wave of breakthrough treatments” and innovative medical research and technologies are created in the country.
Asia
AstraZeneca forms Chinese company to boost innovation
28 November 2017   AstraZeneca and the Chinese Future Industry Investment Fund have partnered to establish a company focused on discovering, developing and commercialising new medicines.

More features

Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations